

Factsheet 2021



Learn more about Formycon
www.formycon.com



COMPANY DESCRIPTION

FORMYCON is a leading and independent developer of high-quality biopharmaceutical medicines, especially biosimilars. These are follow-on versions of biopharmaceuticals, for which exclusivity has expired. FORMYCON focuses on treatments in ophthalmology, immunology and on other key chronic diseases and currently has four biosimilars in development. Because of their size and structural complexity, and their production using living cell systems, biosimilars require very significant time, effort and expertise, both in their development and in their subsequent production. FORMYCON's activities span the entire range from technical-pharmaceutical development to clinical trials, all the way through to preparation of dossiers for regulatory approval. Based on the clinically validated experience with antibodies and antibody fusion proteins, the Company initiated the development of an ACE2 antibody fusion protein (FYB207) in March 2020, shortly after the COVID-19 pandemic broke out in Europe.

DEVELOPMENT PIPELINE

Biosimilar Candidate	Reference (INN)	Disease area	Partner	Preclinical Phase	Clinical Phase I	Clinical Phase III	BLA Filing
FYB201	LUCENTIS® (ranibizumab)	Ophthalmology	Bioeq AG	✓	✓		In Progress
FYB202	STELARA® (ustekinumab)	Immunology	Aristo Pharma GmbH	✓	Ongoing since October 2019	Ongoing since November 2020	
FYB203	EYLEA® (afiblervcept)	Ophthalmology	Klinge Biopharma GmbH	✓		Ongoing since August 2020	
FYB206	Undisclosed	Undisclosed	not partnered	Ongoing			
Product	Innovation	Disease area	Partner	Preclinical Phase	Clinical Phase I-III	BLA Filing	
FYB207	INNOVATIVE PRODUCT	COVID-19	not partnered	Ongoing	Planned to be started in 2021		

STRATEGY & GOALS

FORMYCON is specifically concentrating on the "third wave" of biosimilars, namely follow-on products for blockbuster biopharmaceuticals with patent expiries beginning in the year 2020. The company seeks to license out its biosimilar candidates to cooperation partners once certain defined development milestones have been attained to further develop these through to regulatory approval together with the respective partner company. The FORMYCON Group is currently focusing on research and development activities for both its own and out-licensed biosimilar projects, which are the source of its current revenues. After successful approval of the biosimilar candidates, FORMYCON will also participate in the subsequent marketing revenues. Because FORMYCON has focused its efforts on this generation of biosimilars at a timely stage, the company has been able to carve out for itself a unique and leading position in this market space. It's the strategic goal to further strengthen that status and, as a leading independent developer of biosimilars, to assume a key role in this global market. Biosimilars are the drugs of the future. Through their proven efficacy, cost efficiency and high standard of quality, biosimilar medicines are already making a major contribution towards enabling patient access to effective medical treatments. Through its biosimilars, FORMYCON will help not only patients around the world but also contributes to ease the financial strains on the world's healthcare systems.

FACTS

Founded	2007
Headquarters	Planegg / Munich
Employees	> 100
Management	Dr. Carsten Brockmeyer (CEO) Dr. Nicolas Combé (CFO) Dr. Stefan Glombitzka (COO)
Supervisory Board	Dr. Olaf Stiller (Chairman) Peter Wendeln (Deputy Chairman) Klaus Röhrlig (Member Supervisory Board)

KEY FINANCIALS (in € million)

	2016	2017	2018	2019
Revenue	19.5	29.4	43.0	33.2
EBITDA	-4.1	-1.5	7.1	-1.4
Net Income	-4.1	-1.6	7.1	-2.3
Equity Ratio (in %)	82.9	82.9	83.9	90.0

EXTRACT FROM HIGHLIGHTS 2021 / 2020

JAN 2021	Formycon's Scientific Collaboration Partners present FYB207 results at International Keystone Symposium
DEC 2020	Formycon reports on Virtual Annual General Meeting 2020
DEC 2020	Innovative SARS-CoV-2 Blocker from Formycon completely prevents Infection of Cells
NOV 2020	Chief Operating Officer Dr. Stefan Glombitzka appointed to Formycon AG's Management Board for another Four Years
NOV 2020	Formycon reports its Nine-Month-Figures for 2020
NOV 2020	Formycon and Bioeq announce Launch of Phase III Study of FYB202, a Biosimilar Candidate for Stelara® (Ustekinumab)
NOV 2020	Formycon informs about the modified BLA-Submission Strategy for its Lucentis® Biosimilar-Candidate FYB201

FINANCIAL CALENDAR

Publication of Annual Report 2020	May 2021
Statement Q1 / 2021	June 2021
Publication of Half-Year Report 2021	September 2021
Annual General Meeting 2021	September 27, 2021
Statement Nine-Month Figures 2021	November 2021

MARKET DATA

ISIN	DE000A1EWVY8
Market Segment	Frankfurt, Stock Exchange „Scale“
Market Capitalization	~ € 750 million
Outstanding Shares	11,046,500
Shareholder Structure	15 % Institutional Investors 35 % Family Offices 15 % Founders and Management 35 % Free Float

CONTACT: Sabrina Müller Corporate Communications & Investor Relations

Phone + 49 89 86 46 67 149

E-Mail: sabrina.mueller@formycon.com

This document may contain forward-looking statements and information which are based on our current expectations and certain assumptions. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, performance of the company, development of the products and the estimates given here. Such known and unknown risks and uncertainties comprise, among others, the research and development, the regulatory approval process, the timing of the actions of regulatory bodies and other governmental authorities, clinical results, changes in laws and regulations, product quality, patient safety, patent litigation, contractual risks and dependencies from third parties. With respect to pipeline products, FORMYCON AG does not provide any representation, warranties or any other guarantees that the products will receive the necessary regulatory approvals or that they will prove to be commercially exploitable and/or successful. FORMYCON AG assumes no obligation to update these forward-looking statements or to correct them in case of developments which differ from those anticipated. This document neither constitutes an offer to sell nor a solicitation of an offer to buy or subscribe for securities of FORMYCON AG. No public offering of securities of FORMYCON AG will be made nor is a public offering intended. This document and the information contained therein may not be distributed in or into the United States of America, Canada, Australia, Japan or any other jurisdictions, in which such offer or such solicitation would be prohibited. This document does not constitute an offer for the sale of securities in the United States.